What Happened?
Irvine, CA-based Tarsus-Pharmaceuticals Resigned Leo Greenstein as Chief Financial Officer
About the Company
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
About the Person
Leo Greenstein is Chief Financial Officer at Tarsus Pharmaceuticals. Previously, Leo held various senior HR leadership roles in the industry.
Info Source
News
Short Profile